The aim of this study was to examine the level of and predictors of statin nonadherence and discontinuation among older adults.
Introduction
Statins (hydroxymethylglutaryl-CoA reductase inhibitors) are one of the most commonly prescribed pharmacotherapies for the prevention and treatment of cardiovascular disease (CVD) [1] , and their use has increased over the past decades. In Australia, 34.2% of adults aged 65 years and over were dispensed statins in 2007 and this proportion increased to 44 .1% in 2016 [2] . This translates into a 29% increased likelihood of being dispensed a statin in 2016 compared to 2007 (incidence rate ratio 1.29, 95% confidence interval [CI] 1.28-1.31) [2] .
Despite statins being well tolerated and inexpensive due to increased availability of generic versions, many older adults prescribed statins do not adhere. Discontinuation is also common among people prescribed statins for both primary and secondary prevention [3, 4] . A recent systematic review, including data from more than 3 million older statin users from over 40 countries, found that 65% were nonadherent and nearly 40% discontinued within four years [5] . The proportion of users who were nonadherent or discontinued statins increased sharply within the first year before assuming a constant decline.
Multiple demographic, health system, comorbid and treatment-related factors have been reported to predict nonadherence and discontinuation of statin therapy [6] [7] [8] .
In a meta-analysis of data from over 1.8 million older statin users across 13 countries [6] , female gender was associated with increased nonadherence, while the association between age and statin nonadherence or discontinuation was inconsistent. The absence of comorbidities such as hypertension (odds ratio [OR] 1.13, 95% CI 1.07-1.20) and diabetes (OR 1.09, 95% CI 1.04-1.15) was associated with an increased likelihood of statin discontinuation but no effects of prescriber type were observed. Interestingly, no significant associations were noted between nonadherence or discontinuation and the statin type (i.e., active ingredient) [6] .
Greater insight into the determinants of statin nonadherence and discontinuation is important because both are associated with poor clinical outcomes [4, 9] . For example, people who are adherent to their statins are less likely to develop CVD than nonadherent individuals (risk ratio [RR] 0.85, 95% CI 0.81-0.89) [10] . Similarly, mortality is up to three times higher in patients who discontinue their statin medication following myocardial infarction (MI) than those persisting with therapy [11, 12] . Because the likelihood of statin nonadherence and discontinuation is highest during the first treatment year [5, 13] , improved understanding of the factors associated with first-year nonadherence and discontinuation may support the design of interventions to optimize statin use. Thus, in the present study, we aimed to identify key predictors of first-year statin nonadherence and discontinuation among a large cohort of older people.
Methods

Study design and data sources
The data used in this study were drawn from the Pharmaceutical Benefits Scheme (PBS) records covering a 10% random sample of the Australian population [14] . The PBS is the part of Australia's universal healthcare scheme that subsidizes the costs of prescription medications for Australians [15] . The PBS dataset includes item numbers of drugs dispensed and strength, basic demographic information (sex, years of birth and death), dates of dispensing and quantity of medication supplied, pharmacy location (state) and concession card status. Clinical and diagnostic information such as laboratory test results are not recorded. The supplied data were anonymized, with each individual being ascribed a unique code.
Study cohort
The study population included all adults aged ≥65 years who received at least one statin dispensation between 1 January 2014 and 31 December 2015, the first dispensation date being the index date. We defined a new statin user as any individual dispensed a statin in this period who had not had a statin dispensed in the previous 12 months. Only individuals who survived 12 months from initiation were included.
Outcomes
We calculated one-year statin adherence via the proportion of days covered (PDC) [16] . We assumed a statin dose of one tablet per day [17] and divided the number of days on which a person had a statin on hand by 365 days. The days for which statin medication were available was adjusted if a person refilled earlier than expected (stockpiled). Individuals who achieved a PDC < 0.80 during the 12 months of follow-up were considered to be nonadherent [16] . The PDC of ≥0.80 is regarded as the level of adherence for which complete benefits of statin therapy can be expected [18, 19] . Under the PBS, people are typically dispensed a 30-day supply of statin medication. Thus, as in our prior studies [20, 21] , we considered discontinuation to have occurred if there were 90 or more days without statin coverage. All statins were considered as one, and thus persons switching between different statins were not considered to have discontinued treatment.
Exposure
Statin dispensations were identified from the PBS data using their World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system codes [22] . We included both single active ingredient and combination products of five statins; atorvastatin, simvastatin, rosuvastatin, pravastatin and fluvastatin. Pitavastatin is not reimbursed through the PBS, cerivastatin has been withdrawn from the market [23] and lovastatin is not available in Australia, so these products were therefore not captured in our analysis.
Covariates
We characterized users who were nonadherent or discontinued statin therapy by sex, age (65-74, 75-84 and ≥85 years), prescriber type (general medical practitioner [GP] or other prescriber), statin type, nicotine dependence, comorbidities, use of other cardiovascular-related pharmacotherapies (e.g., anticoagulants) and polypharmacy. Because clinical data are not included in the PBS data, we determined comorbidities via an adapted RxRisk-V tool [24, 25] (see Supplemental Table S1 for codes). The RxRisk-V algorithm relies on medication records to ascribe comorbidity. In our study, each person's 12-month medication record prior to statin initiation was used to determine comorbidities. We assessed polypharmacy as dispensing of five or more different medications during the 3-month period prior to statin initiation.
Statistical analyses
We performed descriptive analyses of nonadherence and discontinuation of statins based on age, sex, comorbidities, use of other cardiovascular therapies, lifestyle factors and polypharmacy. We used a multivariable logistic regression analysis via a backwards stepwise approach [26] to examine the association of statin nonadherence and discontinuation with various factors. This means that variables were removed iteratively until all remaining variables had a P-value < 0.05. Because a myriad of factors, such as changes in medication availability or clinical practice and social factors including negative media coverage [27, 28] , can influence patients' adherence and continuation of therapy, we included the year of initiation in the model. Nonadherence and discontinuation were considered as separate outcomes. We utilized a bootstrap simulation approach [29] with 1000 simulations to confirm the selection of the statistically significant predictor variables. Additionally, we constructed separate models for concessional and general beneficiaries because they have different socioeconomic and demographic profiles and are subject to different subsidy/co-payment levels [30] . We present the adjusted ORs and 95% CIs for the predictors of nonadherence and discontinuation each for concessional and general beneficiaries. All analyses were performed with STATA software (Stata/IC v15.1; StataCorp, College Station, TX, USA). The study received approval from the Monash University Human Research Ethics Committee.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [31] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [32] .
Results
Baseline characteristics
We compiled a cohort of 22 340 older Australians (mean age 73.1 years, standard deviation [SD] 6.8; 48.5% females) who commenced statin therapy between 1 January 2014 and 31 December 2015. Of the cohort, 78.3% (n = 17 499) were concession card holders (mean age 74.0 years, SD 6.9; 51.7% females) and 21.7% (n = 4841) were general beneficiaries (mean age 70.1 years, SD 5.7; 36.7% females). There were significant differences in the prevalence of comorbidities among the concessional and general beneficiaries. For example, while depression was present in 22.2% of concessional beneficiaries, the prevalence of depression among the general beneficiaries was 10.7%. Likewise, while 8.9% of concessional beneficiaries had hypothyroidism, the proportion of general beneficiaries with hypothyroidism was 5.7%. Statin therapy was initiated by a GP in 65.6% of the overall cohort. Atorvastatin, rosuvastatin, simvastatin and other statins (fluvastatin or pravastatin) were prescribed to 45.3%, 45.1%, 7.2% and 2.4% of the cohort at initiation, respectively (Table 1) .
Patterns and predictors of first-year nonadherence
Over the one-year follow-up period, the mean PDC among the cohort was 0.62 ± 0.35 (concessional beneficiaries 0.63 ± 0.35; general beneficiaries 0.57 ± 0.33). Figure 1 illustrates the cumulative distribution of the PDC over one year for both concessional and general beneficiaries. In total, 55.1% of older adults were nonadherent to their statin therapy (concessional beneficiaries = 52.6%; general beneficiaries = 64.2%). Among the concessional beneficiaries, individuals aged ≥85 years experienced an increased likelihood of nonadherence (OR 1.19, 95% CI 1.07-1.33) compared to those aged 65-74 years. In contrast, individuals aged 75-84 years were no more likely to be nonadherent than those aged (Table 2) . For the general beneficiaries, hypertension and use of antiplatelets were associated with a lower likelihood of nonadherence, whereas initiation by a GP was associated with an increased likelihood of nonadherence (Supplemental Table S2 ).
Predictors of first-year discontinuation
Over the one-year follow-up period, 44.7% of the cohort discontinued their statin medication (concessional beneficiaries = 43.1%; general beneficiaries = 50.4%). Among the concessional beneficiaries, discontinuation increased with age such that compared to those aged 65-74 years, persons aged 75-84 and ≥85 years experienced an 11% and 38% higher likelihood of discontinuation, respectively (OR (Table 3) . Having anxiety or pain disorder was also associated with a higher likelihood of statin discontinuation. For the general beneficiaries, hypertension and polypharmacy were associated with a lower likelihood of discontinuation. The patterns of discontinuation as per the different statin types were consistent with that observed among the concessional beneficiaries (Supplemental Table S3 ).
Discussion
In this observational study involving a large cohort of older adults, we found that over 55% were nonadherent and more than two in five discontinued their statin medication during the first year of therapy. Moreover, the likelihood of nonadherence or discontinuation varied according to individual factors such as age, presence of comorbidities, use of other cardiovascular therapies or the type of statin prescribed and the prescriber. Factors associated with statin nonadherence and discontinuation
The one-year nonadherence and discontinuation rates observed in our cohort are slightly higher than those reported in other studies. For example, among US age-qualified Medicare part D beneficiaries who were enrolled in stand-alone prescription drug plans (PDPs) from 2007 to 2008 and were prescribed statins, the proportion of people who were nonadherent at one year was 31.5% [33] . Similarly, among older Finnish people prescribed statins, just 13% had discontinued at one year [34] , whereas a study based on a cohort of older adults from the Netherlands reported one-year statin discontinuation of <30% [35] . Overall, taken together with prior research [5] , our results support the need for multifaceted interventions to improve statin adherence among older people [36] .
Statin nonadherence and discontinuation were particularly high among people aged ≥85 years. A similar study involving a cohort of stroke survivors found lowest statin adherence rates among people aged ≥85 years [37] . This may be because there is limited evidence to support the benefits of statin therapy for people in this age group, particularly for primary prevention [38] . In addition, people in this age group may be at greater risk of statin-induced adverse events which could increase discontinuation [39, 40] .
Diabetes was associated with an increased likelihood of nonadherence and discontinuation. This may be attributed to a high medication burden among this population or as a result of the potential adverse impact of statin therapy on glycaemic control, although contemporary guidelines recommend that statins be prescribed to all older adults with diabetes aged 40 years or over [41] . However, we found that polypharmacy was associated with lower nonadherence and discontinuation. Similar to our results, a higher number of concurrently prescribed medications has been associated with lower nonadherence and discontinuation in prior studies [42, 43] . This may be because people with polypharmacy have cardiovascular comorbidities that increase the perceived importance of adherence to statins. As noted in recent systematic reviews [5, 6] , older adults who perceive themselves to be at increased risk of CVD are less likely to be nonadherent or discontinue their statin medication. This may explain the lower likelihood of nonadherence or discontinuation among those with cardiovascular-related comorbidities such as hypertension, angina and CHF. We also speculate that people initiated on statins by GPs may be at lower risk of CVD compared to those initiated by a specialist, which may explain their higher likelihood of nonadherence or discontinuation [44] . We found that anxiety was associated with an increased likelihood of statin nonadherence and discontinuation. Previous studies have noted high medication nonadherence and discontinuation among persons with anxiety [42, 45] . In particular, older adults with anxiety may show greater concerns about statininduced adverse events; thus clinicians should intensify patient communication and education not only towards explaining the likelihood of adverse effects but also of any potential benefits of statin therapy [36, 42] .
The predictors of nonadherence and discontinuation were similar for concessional and general beneficiaries. Regardless, statin nonadherence and discontinuation rates were higher among the general beneficiaries than the concessional cohort. The differences in statin nonadherence and discontinuation could be due to multiple factors including sociodemographic differences [30] . Internationally, higher co-payments have been associated with increased likelihood of nonadherence and discontinuation among statin users with a recent meta-analysis noting higher copayment to be associated with 61% greater odds of statin discontinuation (OR 1.61, 95% CI 1.53-1.70) [6] . Thus, the lower subsidy/higher co-payment among the general beneficiaries could be a factor in the patterns of statin nonadherence and discontinuation observed. To minimize statin nonadherence, it may be important to reduce financial barriers [6, 46] .
Limited studies have examined the predictors of first-year statin nonadherence and discontinuation among older adults. Our study, which is based on a large cohort of older adults from a country with a universal healthcare system, fills this gap by providing new data on the factors associated with statin nonadherence and discontinuation useful for informing the design of interventions. A number of study limitations warrant mention. In most Australian states the PBS does not cover people who are in hospitals, and therefore it is possible that we may have overestimated nonadherence or discontinuation for people who were hospitalized within the one-year follow-up period. Similarly, while prescribing of statins for every other day is uncommon [17] , by assuming a dosage of one tablet per day for all those in our cohort (every day dosing), those prescribed statins every other day would be classified as nonadherent. Also, by using medications as a surrogate to identify persons with comorbidities, people on non-pharmacological approaches for managing their condition may have been missed. Regardless, the Rx-Risk-V tool that was used in identifying comorbidities has been validated and widely used by Australian and international researchers to ascertain the presence of chronic morbidities [25, 47] . We were also unable to stratify our results according to statin indication and future studies should examine predictors specifically for people being prescribed statins for primary and secondary prevention. Also, people who discontinue their statin medication may restart in the future [48] , but this has not been captured in our analyses. Furthermore, we do not know the reasons why people were nonadherent or discontinued their statin medication as this information is not recorded in the PBS data. Further investigations into self-reported reasons for being nonadherent or discontinuing therapy could strengthen the development of targeted 
Conclusions
Among older adults prescribed statins, first-year nonadherence and discontinuation are high, with over half being nonadherent and more than two in five discontinuing statin medication. The likelihood of an older adult being nonadherent or discontinuing statin therapy varied according to patient demographics, lifestyle factors, comorbidities, statin type prescribed and prescriber characteristics. Our results reiterate the need for multifaceted interventions to reduce statin nonadherence and discontinuation among older adults. In addition, certain population sub-groups, such as those aged ≥85 years and people with diabetes or anxiety, may require additional attention to improve adherence.
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